Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 50,439 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer, Clear all

Conditions: Breast Cancer Female
Interventions: Presentation of personal breast cancer risk estimate; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 39 Years to 74 Years · Female only
Enrollment: 726 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • St Louis, Missouri

Conditions: Pregnancy, Infertility
Interventions: Timed intercourse, Microsurgical varicocelectomy, Intrauterine insemination; Behavioral · Procedure
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Aurora, Colorado • New Haven, Connecticut • Ann Arbor, Michigan + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: MPDL3280A, Carboplatin, Nab-paclitaxel; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York

Conditions: Carcinoma, Hepatocellular
Interventions: Onartuzumab, Sorafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Sarasota, Florida • Baltimore, Maryland • New York, New York + 2 more

Conditions: Breast Cancer
Interventions: DNA methylation analysis, microarray analysis, polymerase chain reaction, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 182 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 4
States / cities: Indianapolis, Indiana • Baltimore, Maryland • Rochester, Minnesota + 1 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Sorafenib, Ipilimumab, Cabozantinib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Pensacola, Florida + 7 more

Conditions: Breast Neoplasms, Breast Cancer, Cancer of Breast, Cancer of the Breast
Interventions: Bright blue-green light using light visor cap, Dim red light using light visor cap, European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance, Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue, Digital foot candle datalogging light meter (Extech Instrument, Model SDL400), Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA), Horne-Ostberg Morningness-Eveningness Questionnaire, Daily Fatigue and Sleep Log; Other · Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 21 Years and older · Female only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: SoluMatrix™ Abiraterone Acetate, Methylprednisolone; Drug
Lead sponsor: GU Research Network, LLC; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Wichita, Kansas • Lincoln, Nebraska • Omaha, Nebraska

Conditions: Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions: Ipilimumab, Nivolumab, Pembrolizumab, Quadrivalent Inactivated Influenza Vaccine, Resection, Nivolumab + Relatlimab; Biological · Procedure
Lead sponsor: Carlo Contreras; Other
Eligibility: 18 Years to 99 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neoplasms, Breast
Interventions: Pazopanib, Lapatinib, paclitaxel, carboplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Cleveland, Ohio • Nashville, Tennessee

Conditions: Recurrent Atypical Teratoid/Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS
Interventions: Lumber Puncture, Blood Specimen Collection, Magnetic resonance imaging (MRI), Gemcitabine, Paxalisib, Tumor Biopsy; Procedure · Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 39 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2036
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Seattle, Washington

Conditions: Refractory Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma
Interventions: ixazomib citrate, dexamethasone, pomalidomide; Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 5
States / cities: Scottsdale, Arizona • Duarte, California • Atlanta, Georgia + 2 more

Conditions: Bladder Cancer, Renal Pelvis Cancer, Ureter Cancer
Interventions: gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Pigmented Villonodular Synovitis, PVNS, Giant Cell Tumor of the Tendon Sheath, GCCTS, Tenosynovial Giant Cell Tumor Localized or Diffused Type, GCTS
Interventions: MCS110, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 7
States / cities: San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 4 more

Conditions: Osteosarcoma, Ewing's Sarcoma, Neuroblastoma, Brain Tumors, Leukemia
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Cleveland, Ohio

Conditions: Amputation
Interventions: Targeted Muscle Reinnervation; Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Breast Benign, Malignant Neoplasm of Breast, Breast Malignant Tumor
Interventions: Magnetic Resonance Imaging (MRI); Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 80 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Fatigue
Interventions: Energy Conservation Work Simplification Education; Behavioral
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Colon Cancer
Interventions: grilled hamburger (7 oz) with no vegetables, grilled hamburger (7 oz) with steamed broccoli and Brussels sprouts (3g/kg body weight combined), grilled hamburger (7 oz) with steamed parsnips, fresh parsley, and celery sticks (3g/kg body weight combined), grilled hamburger (7 oz) with steamed broccoli, Brussels sprouts, and parsnips plus fresh parsley and celery sticks (6g/kg body weight combined).; Other
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Lymphoma, Large Cell, Diffuse, Lymphoma, Mixed Cell, Diffuse, Primary Mediastinal Large B-Cell Lymphoma
Interventions: CT-011; Drug
Lead sponsor: CureTech Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 20
States / cities: La Jolla, California • San Diego, California • Atlanta, Georgia + 14 more

Conditions: Pancreatic Neoplasms
Interventions: Gemcitabine with escalating ascorbic acid; Drug
Lead sponsor: Joseph J. Cullen; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Unresectable Solid Tumor, Metastatic Cancer
Interventions: Proton GRID Radiotherapy; Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: Narrative visualization, Standard self-regulation; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years to 79 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Galveston, Texas

Search by objective public record fields.

Understanding and Addressing Rejection of Personalized Breast Cancer Risk Information in Women

Microsurgical Varicocelectomy Versus No Surgery in Men With a Palpable Varicocele and an Abnormal Semen Analysis

Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC

A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma

DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer

Bright Light on Fatigue in Women Being Treated for Breast Cancer

Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Informed Consent in Pediatric Cancer Trials

Targeted Muscle Reinnervation Study (TMR)

Low-field MRI for Breast Cancer Screening

Feasibility and Effectiveness of an Internet-based Intervention to Manage Fatigue in Breast Cancer Survivors

Vegetable Intake Effect on Heterocyclic Amine Metabolism

CT-011 MAb in DLBCL Patients Following ASCT

A Research Trial of High Dose Vitamin C and Chemotherapy for Metastatic Pancreatic Cancer

Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy

Narrative Visualization for Breast Cancer Survivors' Physical Activity